Uncategorized Archives - Page 2 of 148

ThursdayJan 15, 2026 9:00 am

Michigan State University Research Says Suppressing Postoperative Pain Could Delay Healing

The normal practice after someone has undergone a surgical procedure has been to administer anti-inflammatory medications. However, new research conducted at Michigan State University (MSU) suggests that this could be counterproductive and may be the reason why some patients develop chronic pain that lasts for years after their surgery. The study found that allowing inflammation to happen naturally expedited the recovery process after injury or surgery and that pain ceased a lot faster if inflammation wasn’t blocked. Associate Professor Geoffroy Laumet, the senior author of the study, explains that the research team was surprised when they found that blocking inflammation…

WednesdayJan 14, 2026 10:30 am

Soligenix Inc. (NASDAQ: SNGX) Advances Solutions for Hard-to-Diagnose CTCL

CTCL is recognized by clinicians as one of the most difficult cancers to diagnose accurately in its early stages. Delayed diagnosis has meaningful clinical consequences. Within this challenging diagnostic and treatment landscape, Soligenix is advancing a novel therapeutic approach for CTCL through its development of HyBryte(TM). Cutaneous T-cell lymphoma, or CTCL, is a rare form of non-Hodgkin lymphoma that primarily affects the skin, often presenting with symptoms that closely resemble common dermatologic conditions such as eczema or psoriasis, leading to frequent misdiagnosis and delayed treatment. These diagnostic delays can allow the disease to progress silently for years, increasing patient suffering…

WednesdayJan 07, 2026 9:00 am

LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Is ‘One to Watch’

LIXTE is advancing a first-in-class PP2A inhibitor platform designed to enhance, rather than replace, established chemotherapy and immunotherapy regimens. The company is conducting multiple active clinical trials in solid tumors with significant unmet medical need, supported by academic and industry collaborations. LIXTE’s scientific strategy is protected by a comprehensive patent portfolio, with management noting no known direct competitors targeting PP2A inhibition. Strategic actions in 2025, including the acquisition of Liora Technologies and a registered direct offering completed in December 2025, reflect an effort to broaden capabilities and strengthen operational flexibility. Expansion of the ovarian clear cell carcinoma trial in December…

TuesdayDec 23, 2025 9:45 am

Oncotelic Therapeutics Inc. (OTLC) Unveils Breakthrough Nanomedicine Platform, Expands Everolimus (Afinitor(R)) Pipeline

OTLC’s Deciparticle(TM) platform reliably formulates diverse hydrophobic drugs—including macrolide mTOR inhibitors, peptides, and polyketides—into uniform, IV-ready nanoparticles. Current Preclinical PK data show that Sapu003, the intravenous Deciparticle(TM) formulation of Everolimus (Afinitor(R)), cuts down gastrointestinal drug accumulation by up to 67-fold compared to oral dosing. These advancements highlight a quickly expanding immunology and oncology pipeline built on modular, cGMP-ready nanomedicine engineering. Oncotelic Therapeutics (OTCQB: OTLC) is rapidly emerging as a key player in next-generation drug delivery, with a scalable nanotechnology platform that can transform the paradigms of immunology and oncology treatments. Leveraging Sapu Nano, the company’s clinical-stage nanomedicine, it unveiled new…

MondayDec 22, 2025 9:00 am

Soligenix Inc. (NASDAQ: SNGX) Extends SGX302 Clinical Success in Phase 2A Psoriasis Study

Soligenix reported that SGX302 was well tolerated by all patients in cohort 3, with no drug-related adverse events identified during the treatment period. An optimized gel formulation was designed to improve the patient experience, with both easier dispensation and skin application. SGX302 utilizes visible light-activated synthetic hypericin, a first-in-class photodynamic therapy mechanism. Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products for rare diseases where unmet medical need exists, announced extended top line results from its Phase 2a clinical trial of SGX302 (synthetic hypericin) in patients with mild-to-moderate psoriasis. The updated findings highlight clinical improvements with an optimized gel formulation…

FridayDec 19, 2025 10:30 am

Soligenix Inc. (NASDAQ: SNGX) Advances Ricin Vaccine amid Toxin Threat

A recent report from India is a stark reminder of ricin’s accessibility and the pressing need for effective countermeasures. Ricin is a potent toxin capable of causing death within days of exposure because it stops protein synthesis inside cells, leading to organ failure. Soligenix has demonstrated meaningful preclinical efficacy for its ricin vaccine candidate. A recent “Times of India” report spotlighted the danger posed by ricin, a highly toxic plant-derived compound with no known antidote and a history of attempted misuse by extremist actors. Soligenix (NASDAQ: SNGX), a biopharmaceutical company focused on biodefense solutions, is developing a vaccine candidate known as RiVax(R) to protect against ricin…

FridayDec 19, 2025 9:00 am

US House Passes Republican Healthcare Bill, ACA Extension Left Out

The U.S. House of Representatives passed a healthcare bill that didn’t include an extension of the ACA tax credits that were at the heart of the recent government shutdown. This bill now heads to the Senate for consideration. On Wednesday, the exclusion of a provision extending the ACA tax credits triggered a revolt within the GOP ranks as some moderates in their ranks joined Democrats in signing a discharge petition that would compel the House to conduct a vote on extending the tax credits for 3 years. However, none of the Republicans who signed this petition eventually voted against the…

ThursdayDec 18, 2025 10:00 am

Chronic Inflammation Could Be the Missing Key to Understanding Long Covid

In the U.S. about 15 million individuals live with long Covid, according to Department of Health & Human Services. For a long time, the scientific community has struggled to find out why some individuals who got infected with Covid-19 recovered fully while others developed lingering symptoms that came to be described as long Covid. Now a new study has established that the key driver among people with long Covid could be chronic inflammation and this opens new pathways to treating the condition. The study, conducted by a team at Beth Israel Medical Center and Harvard University analyzed blood samples taken from 140 individuals who never suffered from Covid, those who got infected…

WednesdayDec 17, 2025 9:00 am

Oncotelic Therapeutics Inc. (OTLC) Leverages Nanoparticles to Re-Imagine Drug Delivery in Oncology

Research indicates that the advantages of nanoparticle delivery in pharma are significant Oncotelic Therapeutics has advanced nanoparticle-based delivery strategies through its joint venture entity, involving its Deciparticle platform Oncotelic is leveraging the very concepts of nanoparticle-mediated delivery in a real-world clinical context In the evolving landscape of pharmaceutical innovation, nanoparticles are rapidly transforming how we think about drug delivery, and Oncotelic Therapeutics (OTCQB: OTLC) is placing itself at the heart of that transformation by applying ultra-small carrier technologies to elevate existing cancer therapies. The company is pioneering how nanotechnology can enhance bioavailability, precision targeting and therapeutic performance of anticancer compounds.…

TuesdayDec 16, 2025 10:00 am

Researchers Use Supplements to Produce Remarkable Outcomes in Brain Cancer Treatment

A new study done in India has produced results that bring into question the longstanding assumption that treating cancer requires tumors to be destroyed. The researchers attained remarkable results by using another approach, treating the tumor rather than attacking it, and their approach was effective in taming the aggressiveness of glioblastoma while also toning down many biomarkers that indicate the severity of the cancer. For a while, many researchers have been growing in conviction that the way cancer is treated needs to change from efforts geared at destroying cancer cells (through chemotherapy, surgery and radiation) to regarding cancer as a wound that needs to be helped to heal. This thinking was first…